A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries

@article{Haugh2017ATI,
  title={A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries},
  author={M. Haugh and Viviane Gresset-Bourgeois and B. Macab{\'e}o and A. Woods and S. Samson},
  journal={Expert Review of Vaccines},
  year={2017},
  volume={16},
  pages={545 - 564}
}
ABSTRACT Introduction: Vaxigrip, a trivalent split-virion, inactivated vaccine available since 1968 has been in use longer than any other influenza vaccine. It is the most widely-used influenza vaccine, with more than 1.8 billion doses distributed in more than 120 countries. Areas covered: The significant body of evidence that confirms the efficacy, effectiveness, immunogenicity, and safety of Vaxigrip in healthy individuals of all ages and at-risk populations is summarized. The results from at… Expand
13 Citations
Quadrivalent inactivated influenza vaccine (VaxigripTetra™)
  • 15
Attitudes of Nursing Home Staff towards Influenza Vaccination: Opinions and Factors Influencing Hesitancy
  • PDF
...
1
2
...

References

SHOWING 1-10 OF 141 REFERENCES
Evaluation of reactogenicity and immunogenicity of two influenza vaccines (vaxigrip and fluarix) in the season 1996-1997.
  • 7
Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults.
  • 25
  • PDF
Clinical experience with inactivated, virosomal influenza vaccine.
  • 54
  • Highly Influential
Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6–35 Months: A Randomized, Controlled Trial
  • 25
  • PDF
A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia.
  • 10
  • PDF
...
1
2
3
4
5
...